IN2012DN06589A - - Google Patents

Download PDF

Info

Publication number
IN2012DN06589A
IN2012DN06589A IN6589DEN2012A IN2012DN06589A IN 2012DN06589 A IN2012DN06589 A IN 2012DN06589A IN 6589DEN2012 A IN6589DEN2012 A IN 6589DEN2012A IN 2012DN06589 A IN2012DN06589 A IN 2012DN06589A
Authority
IN
India
Prior art keywords
mbl
sepsis
infectious diseases
provides
bind
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Super
Jeffrey Charles Way
Donald E Ingber
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of IN2012DN06589A publication Critical patent/IN2012DN06589A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts
    • G01N2333/40—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts from Candida
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/72—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables
    • G01N27/74—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids
    • G01N27/745—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating magnetic variables of fluids for detecting magnetic beads used in biochemical assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IN6589DEN2012 2010-01-19 2011-01-19 IN2012DN06589A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29622210P 2010-01-19 2010-01-19
PCT/US2011/021603 WO2011090954A2 (fr) 2010-01-19 2011-01-19 Opsonine obtenue par génie génétique, pour la détection et le traitement de micro-organismes pathogènes

Publications (1)

Publication Number Publication Date
IN2012DN06589A true IN2012DN06589A (fr) 2015-10-23

Family

ID=44307537

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6589DEN2012 IN2012DN06589A (fr) 2010-01-19 2011-01-19

Country Status (11)

Country Link
US (7) US9150631B2 (fr)
EP (1) EP2526119B1 (fr)
JP (5) JP5959440B2 (fr)
CN (1) CN102947341B (fr)
AU (1) AU2011207626B2 (fr)
CA (1) CA2787376A1 (fr)
DK (1) DK2526119T3 (fr)
ES (1) ES2678143T3 (fr)
IN (1) IN2012DN06589A (fr)
SG (2) SG182577A1 (fr)
WO (1) WO2011090954A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044642A2 (fr) 2005-10-06 2007-04-19 President And Fellows Of Harvard College And Children's Medical Center Corporation Dispositif et procede destines a la separation microfluidique-micromagnetique combinee d'une substance a partir d'un ecoulement continu
ATE534415T1 (de) 2005-12-13 2011-12-15 Harvard College Gerüste zur zelltransplantation
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
WO2010123594A2 (fr) 2009-01-15 2010-10-28 Children's Medical Center Corporation Dispositif pour la filtration de fluides à travers celui-ci et procédé associé
EP2526119B1 (fr) 2010-01-19 2018-05-30 President and Fellows of Harvard College Opsonine obtenue par génie génétique, pour la détection et le traitement de micro-organismes pathogènes
JP6104806B2 (ja) 2010-10-06 2017-03-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 材料に基づく細胞治療のための注射可能孔形成性ハイドロゲル
US20120263771A1 (en) * 2011-03-25 2012-10-18 Receptors Llc Fiber with microbial removal, micro-biocidal, or static growth capability
US20140220617A1 (en) * 2011-04-01 2014-08-07 Children's Medical Center Corporation Dialysis like therapeutic (dlt) device
AU2012284097B2 (en) 2011-07-18 2017-08-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013130875A1 (fr) * 2012-02-29 2013-09-06 President And Fellows Of Harvard College Test rapide de sensibilité aux antibiotiques
EP3662896B1 (fr) 2012-04-16 2024-02-28 President and Fellows of Harvard College Compositions de silice mésoporeuse pour moduler les réponses immunitaires
US20130334120A1 (en) * 2012-06-15 2013-12-19 President And Fellows Of Harvard College Fluid cleansing devices and methods of use
EP3327090A1 (fr) * 2012-07-18 2018-05-30 President and Fellows of Harvard College Modification de surfaces pour une répulsion et une liaison ciblée simultanées de fractions désirées
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
EP3848044A1 (fr) 2013-05-21 2021-07-14 President and Fellows of Harvard College Compositions se liant à l'hème manipulées et leurs utilisations
US9791440B2 (en) 2013-07-15 2017-10-17 President And Fellows Of Harvard College Assays for antimicrobial activity and applications thereof
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
DE102014206444A1 (de) * 2014-04-03 2015-10-08 Siemens Aktiengesellschaft Verfahren für die Molekulardiagnostik zum Anreichern einer Nukleinsäure aus einer biologischen Probe
WO2015168379A2 (fr) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Dispositifs de vaccin combiné et procédés de destruction de cellules cancéreuses
US10357780B2 (en) 2014-10-27 2019-07-23 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
WO2016123573A1 (fr) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Matériaux péritumoraux et intratumoraux pour traitement anticancéreux
WO2016164705A1 (fr) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Dispositifs de piégeage de cellules immunitaires et leurs procédés de fabrication et d'utilisation
US10435457B2 (en) 2015-08-06 2019-10-08 President And Fellows Of Harvard College Microbe-binding molecules and uses thereof
EP3349823B1 (fr) 2015-09-14 2022-01-26 Medisieve Ltd Appareil de filtration magnétique
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
WO2017143024A2 (fr) * 2016-02-16 2017-08-24 President And Fellows Of Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation
US11919971B2 (en) 2016-05-16 2024-03-05 President And Fellows Of Harvard College Aqueous biomolecule coupling on CO2-plasma-activated surfaces
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
JP7071040B2 (ja) 2016-07-28 2022-05-18 メディシーブ リミテッド 磁性混合器および方法
WO2019064463A1 (fr) * 2017-09-28 2019-04-04 学校法人中部大学 Procédé et dispositif pour la concentration de virus ou de bactérie par bioaffinité
KR102084688B1 (ko) * 2018-06-18 2020-03-04 울산과학기술원 다중 프로브 혼성화를 이용한 미생물 검출 방법
CN110628624B (zh) * 2019-02-01 2022-07-15 传鸣(宁波)化学科技有限公司 一种磁性微生物捕获材料及微生物捕获方法
CN110294810B (zh) * 2019-06-26 2021-05-04 中国疾病预防控制中心传染病预防控制所 一种含有人IgG1Fc和甘露聚糖结合凝集素C端的重组蛋白
US20230270927A1 (en) 2019-12-23 2023-08-31 Miraki Innovation Think Tank Llc Compositions, devices and methods for diagnosing and treating infectious disease
US20230054472A1 (en) 2019-12-23 2023-02-23 Miraki Innovation Think Tank Llc Sample preparation and microbial analysis
CN111675825B (zh) * 2020-06-09 2022-06-24 大连工业大学 一种附有胰蛋白酶的微孔膜的制备方法及其在蛋白水解中的应用
CA3196472A1 (fr) 2020-06-12 2021-12-16 Miraki Innovation Think Tank Llc Dosage a ecoulement lateral pour la detection rapide d'agents pathogenes dans des echantillons
US20240001019A1 (en) 2020-07-31 2024-01-04 Miraki Innovation Think Tank Llc Mbl-coated substrates having anti-thrombogenic properties
WO2022046558A1 (fr) 2020-08-28 2022-03-03 Miraki Innovation Think Tank Llc Compositions thérapeutiques comprenant des molécules ciblant des microbes et leur utilisation dans des méthodes de prévention et de traitement d'une maladie infectieuse
WO2022067006A1 (fr) 2020-09-25 2022-03-31 Miraki Innovation Think Tank Llc Compositions, dispositifs et méthodes comprenant des molécules ciblant les microbes pour le diagnostic et le traitement d'une maladie infectieuse
US20230416319A1 (en) 2020-10-01 2023-12-28 Miraki Innovation Think Tank Llc Compositions, devices and methods for identifying, treating and preventing infectious disease using microbe-targeting molecules
WO2022093935A1 (fr) 2020-10-27 2022-05-05 Miraki Innovation Think Tank Llc Compositions, systèmes et méthodes de surveillance de pathogènes à l'aide de molécules ciblant des microbes
WO2022125632A1 (fr) 2020-12-08 2022-06-16 Miraki Innovation Think Tank Llc Cellules exprimant un récepteur antigénique chimérique pour cibler des motifs moléculaires associés aux microbes
WO2022151333A1 (fr) * 2021-01-15 2022-07-21 传鸣(宁波)化学科技有限公司 Mélange pour enrichir des micro-organismes et procédé et application

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5418198A (en) 1977-07-09 1979-02-09 Toshimitsu Niwa Artificial intraretinal device
US4425330A (en) 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
WO1984002193A1 (fr) 1982-12-03 1984-06-07 Du Pont Analyse immunologique a support chromogene
JPS60500548A (ja) 1982-12-03 1985-04-18 イ−・アイ・デユポン・ド・ネモア−ス・アンド・コンパニ− 発色性支持体免疫測定法
JPH0718875B2 (ja) 1987-06-19 1995-03-06 ヤマサ醤油株式会社 血中または体液中の微量物質含有量の測定法
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
JP2868777B2 (ja) 1987-08-20 1999-03-10 チルドレンズ・ホスピタル・コーポレイション ヒトマンノース結合タンパク質
ATE122568T1 (de) 1989-01-25 1995-06-15 Commw Scient Ind Res Org Polypeptide, antigene oder vakzine gegen babesiosis.
US5137810A (en) 1989-04-26 1992-08-11 The University Of North Carolina Method of determining the gram sign of bacteria
DE4018583A1 (de) 1990-06-09 1991-12-12 Henkel Kgaa Modifiziertes verfahren zur direkten herstellung von alkylglykosiden
EP0900521A1 (fr) 1990-07-30 1999-03-10 Novartis AG Proteines insecticides
GB9020075D0 (en) 1990-09-14 1990-10-24 Filler Aaron G Contrast agents for magnetic resonance imaging of axonal transport
JPH04130274A (ja) 1990-09-20 1992-05-01 Kyoto Ikagaku Kenkyusho:Kk 糖蛋白の分析，検出方法
US5783179A (en) 1991-08-09 1998-07-21 Syntex (U.S.A.) Inc. C-reactive protein fragment with immunomodulatory activity
CA2123786C (fr) 1991-11-27 2000-08-01 Lawrence A. Potempa Methode de traitement des viroses par proteine c-reactive
US5405832A (en) 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5874238A (en) 1993-02-26 1999-02-23 Immtech International Inc. Mutant protein and methods and materials for making and using it
US5283238A (en) 1992-04-24 1994-02-01 Immtech International, Inc. Methods of treating cancer using modified C-reactive protein
US6703219B1 (en) 1993-02-26 2004-03-09 Immtech International Inc. Mutant protein and methods and materials for making and using it
IT1271486B (it) 1993-10-12 1997-05-28 Italfarmaco Spa Oligopeptidi immunomodulatori derivati di frammenti della proteina c- reattiva
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
AUPN214095A0 (en) 1995-04-03 1995-04-27 Australian Water Technologies Pty Ltd Method for detecting microorganisms using flow cytometry
WO1997035619A1 (fr) 1996-03-28 1997-10-02 Genitrix, L.L.C. Cellules renforcees par opsonine, et procede de modulation d'une reponse immune a un antigene
ZA973051B (en) 1996-04-24 1998-10-12 Genentech Inc Type c lectins
US6117977A (en) 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
JPH11206378A (ja) 1998-01-23 1999-08-03 Fuso Pharmaceutical Industries Ltd 組換えヒトマンナン結合タンパク質およびその製造方法
US7049099B2 (en) 1998-01-23 2006-05-23 Fuso Pharmaceutical Industries, Ltd. Recombinant human mannan-binding proteins and producing method of the same
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6429192B1 (en) 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
NZ509577A (en) 1998-07-31 2003-01-31 Asahi Chemical Ind Antibodies for ribosmal proteins specific to only one microorganism genus or species
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE60033147T2 (de) 1999-05-14 2007-12-13 Steffen Thiel Rekombinantes menschliches mannan-bindendes lektin
ES2317843T3 (es) 1999-07-13 2009-05-01 Bolder Biotechnology, Inc. Proteinas de fusion de eritropoyetina-inmunoglobulina.
US6503761B1 (en) 1999-10-19 2003-01-07 Kimberly-Clark Worldwide, Inc. Selective removal of contaminants from a surface using articles having magnets
MXPA02007733A (es) * 2000-02-11 2004-09-10 Merck Patent Gmbh Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos.
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
JP2002165591A (ja) 2000-09-25 2002-06-11 Jsr Corp 磁性粒子およびその使用方法
AU2002227184A1 (en) 2000-10-18 2002-04-29 The Board Of Trustess Of The Leland Stanford Junior University Methods for development and use of diagnostic and therapeutic agents
GB0119274D0 (en) 2001-08-08 2001-10-03 Univ Durham Fusion proteins for insect control
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
WO2003054164A2 (fr) 2001-12-19 2003-07-03 Immunex Corporation Polypeptide de lectine de type c, polynucleotide et procedes de fabrication et d'utilisation correspondant
US6844426B2 (en) 2002-02-06 2005-01-18 Toyo Boseki Kabushiki Kaisha Magnetic carrier capable of binding with protein and purification method of protein utilizing the magnetic carrier
JP4959110B2 (ja) 2002-02-07 2012-06-20 マサチューセッツ インスティテュート オブ テクノロジー 抗病原体治療
ES2271515T3 (es) 2002-03-15 2007-04-16 Natimmune A/S Composiciones farmaceuticas que comprenden lecitina de union a manosa.
US20030180814A1 (en) 2002-03-21 2003-09-25 Alastair Hodges Direct immunosensor assay
US7211396B2 (en) 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin
US20050037949A1 (en) 2002-04-24 2005-02-17 O'brien Grace Mannose binding lectin and uses thereof
US20040018611A1 (en) 2002-07-23 2004-01-29 Ward Michael Dennis Microfluidic devices for high gradient magnetic separation
US7629440B2 (en) 2002-08-20 2009-12-08 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
BR0313650A (pt) * 2002-08-20 2007-08-14 Genitrix Llc composição, vetor de expressão, composição de vacina e uso
WO2004024925A2 (fr) 2002-09-10 2004-03-25 Natimmune A/S Proteines chimeres activant la collectine du complement
GB2393728A (en) 2002-10-04 2004-04-07 Nanomagnetics Ltd Magnetic nanoparticles
EP1417965A1 (fr) 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Molécules capables de se lier à des lectines de type-C, leur identification et usages
JP2007525232A (ja) 2003-01-17 2007-09-06 イースロン メディカル インコーポレイテッド レクチンアフィニティー血液透析による血液のウイルス除去方法
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
DE10325752A1 (de) 2003-06-06 2004-12-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Lektin-Konjugate
WO2005040194A2 (fr) 2003-10-24 2005-05-06 Ludwig Institute For Cancer Research Methodes et compositions d'activation et d'inhibition de pdgf-c
AU2004309063B2 (en) * 2003-12-31 2010-10-28 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2005092925A2 (fr) 2004-03-24 2005-10-06 Xencor, Inc. Variantes d'immunoglobuline a l'exterieur de la region fc
SE0401033D0 (sv) 2004-04-20 2004-04-20 Amersham Biosciences Ab Device and method for protein analysis
WO2007001332A2 (fr) 2004-08-04 2007-01-04 University Of Massachusetts Immunoadhesines anti-pathogene
US20090269843A1 (en) 2004-08-20 2009-10-29 Novo Nordisk A/S Hemopexin fusion proteins
US20110098184A1 (en) 2004-10-15 2011-04-28 Day Anthony G Competitve differntial screeing
JP4592756B2 (ja) 2004-10-28 2010-12-08 ドゥビエル カンパニー リミテッド 高分子形マンノース結合型レクチンの大量生産方法
US20060141547A1 (en) 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
US7172906B2 (en) 2004-11-16 2007-02-06 Dade Behring Inc. Reduction of non-specific binding in assays
US8084275B2 (en) 2005-02-08 2011-12-27 Fujifilm Corporation Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface
JP2008535872A (ja) 2005-04-11 2008-09-04 ナットイムネ・アクティーゼルスカブ 免疫障害を持つ個体の処置におけるマンナン結合レクチン（ｍｂｌ）の新規癌適用
US20070031819A1 (en) 2005-04-26 2007-02-08 University Of Washington Microfluidic systems for biological and molecular analysis and methods thereof
BRPI0608766A8 (pt) 2005-05-09 2018-04-17 Biosphere Medical Sa microsfera substancialmente esférica, composição, e, métodos para administração de medicamento e para embolização ativa em um mamífero
US20070231833A1 (en) 2005-05-23 2007-10-04 Arcidiacono Steven M Labeled antimicrobial peptides and method of using the same to detect microorganisms of interest
TWI333959B (en) 2005-08-31 2010-12-01 Academia Sinica Methods and reagents for the analysis and purification of polysaccharides
CA2621632A1 (fr) 2005-09-30 2007-04-12 Caliper Life Sciences, Inc. Dispositif microfluidique utilise pour purifier un constituant biologique au moyen de billes magnetiques
WO2007044642A2 (fr) 2005-10-06 2007-04-19 President And Fellows Of Harvard College And Children's Medical Center Corporation Dispositif et procede destines a la separation microfluidique-micromagnetique combinee d'une substance a partir d'un ecoulement continu
EP2388013A3 (fr) 2005-10-26 2012-03-07 Science & Technology Corporation @ UNM Protéine C réactive et son utilisation pour traiter le lupus érythémateux systémique et des maladies associées
US20070269818A1 (en) 2005-12-28 2007-11-22 Affymetrix, Inc. Carbohydrate arrays
US20090181041A1 (en) 2006-01-23 2009-07-16 Jan Holgersson Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
CA2641271A1 (fr) 2006-02-03 2008-03-13 Microchip Biotechnologies, Inc. Dispositifs microfluidiques
US8821851B2 (en) 2006-03-23 2014-09-02 The General Hospital Corporation Inflammation-inhibitory serum factors and uses thereof
WO2007111496A1 (fr) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Domaines de reconnaissance d'hydrates de carbone améliorés
EP1862541A1 (fr) 2006-06-01 2007-12-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides dérivés du domaine de type hémopexine de la métalloprotéinase MMP-2
US8273310B2 (en) 2006-09-05 2012-09-25 Samsung Electronics Co., Ltd. Centrifugal force-based microfluidic device for nucleic acid extraction and microfluidic system including the microfluidic device
KR101343034B1 (ko) 2006-09-05 2013-12-18 삼성전자 주식회사 원심력 기반의 단백질 검출용 미세유동 장치 및 이를포함하는 미세유동 시스템
US8088596B2 (en) * 2006-10-10 2012-01-03 Oakland University Method of microorganism detection using carbohydrate and lectin recognition
US8551333B2 (en) 2007-04-05 2013-10-08 The Regents Of The University Of California Particle-based microfluidic device for providing high magnetic field gradients
WO2008131242A1 (fr) 2007-04-18 2008-10-30 Zymogenetics, Inc. Fc à chaîne simple, procédés de fabrication et procédés de traitement
US8292083B2 (en) 2007-04-19 2012-10-23 The Charles Stark Draper Laboratory, Inc. Method and apparatus for separating particles, cells, molecules and particulates
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
EP2162472B1 (fr) 2007-05-30 2013-02-27 Postech Academy-Industry- Foundation Protéines de fusion d'immunoglobuline
CA2698691A1 (fr) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent therapeutique
EP2662384A1 (fr) 2007-10-29 2013-11-13 Virginia Tech Intellectual Properties, Inc. Utilisations de DC-SIGN ET LSECtin porcines,
CA2705160A1 (fr) 2007-11-09 2009-05-14 Anaphore, Inc. Proteines de fusion de lectines liant le mannose pour un traitement de maladie
ES2326109B1 (es) 2007-12-05 2010-06-25 Consejo Superior De Investigaciones Cientificas Microdispositivo de separacion y extraccion selectiva y no invasiva de particulas en suspensiones polidispersas, procedimiento de fabricacion y sus aplicaciones.
WO2009078015A2 (fr) 2007-12-18 2009-06-25 Procognia (Israel) Ltd Procédé et dosage pour la détection de motifs de glycosylation reliés à l'état cellulaire de cellules souches
EP2240774A2 (fr) 2007-12-31 2010-10-20 3M Innovative Properties Company Compositions et procédés de capture de micro-organismes
US20100331240A1 (en) 2008-01-18 2010-12-30 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins
CN101990575B (zh) 2008-03-28 2015-06-17 国立大学法人北海道大学 抗h5亚型a型流感病毒血凝素单克隆抗体
JPWO2009123347A1 (ja) 2008-03-31 2011-07-28 日本たばこ産業株式会社 ウイルス定量法
EP2267119A4 (fr) 2008-03-31 2011-05-25 Japan Tobacco Inc Procédé de concentration de virus
US20100323429A1 (en) 2008-04-10 2010-12-23 Yu-Chen Hu Methods for purifying baculovirus
US8865876B2 (en) 2008-06-02 2014-10-21 California Institute Of Technology Engineered lectin oligomers with antiviral activity
BRPI0909910A2 (pt) 2008-06-03 2016-10-11 Stc Unm "método de tratamento, inibição ou redução da probabilidade de lúpus eritematoso sistêmico (les) ou de um estado de doença secundária, condição ou manifestação associada ao lúpus eritematoso sistêmico ou à púrpura trombocitopênica imunológica em um paciente, composição farmacêutica e seu uso"
JP2010122205A (ja) 2008-08-29 2010-06-03 Sysmex Corp 麻疹ウイルス検出方法、メンブレンアッセイ用試験具およびメンブレンアッセイ用試験キット
US20110159000A1 (en) 2008-09-05 2011-06-30 The Regents Of The University Of California Antibodies with mannose binding lectin effector function for inhibiting pathologic inflammatory conditions
WO2010065765A2 (fr) 2008-12-04 2010-06-10 Aethlon Medical, Inc. Capture par affinité de biomarqueurs circulants
JP5645187B2 (ja) 2008-12-22 2014-12-24 国立大学法人北海道大学 三重螺旋構造を有するタンパク質、およびその製造方法
WO2010078966A1 (fr) * 2009-01-09 2010-07-15 Apogenix Gmbh Protéines de fusion formant des trimères
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
CA2750115A1 (fr) 2009-01-28 2010-08-05 Smartcells, Inc. Lectines de site de liaison modifiees et usage correspondant
WO2011084749A1 (fr) 2009-12-21 2011-07-14 The Research Foundation Of State University Of New York Compositions et méthodes permettant d'inhiber la migration cellulaire à médiation par la mmp9
WO2011091037A2 (fr) 2010-01-19 2011-07-28 President And Fellows Of Harvard College Dispositif et procédé de diagnostic pathogène rapide
EP2526119B1 (fr) 2010-01-19 2018-05-30 President and Fellows of Harvard College Opsonine obtenue par génie génétique, pour la détection et le traitement de micro-organismes pathogènes
EP2665782A2 (fr) 2011-01-19 2013-11-27 President and Fellows of Harvard College Surfaces glissantes à stabilité élevée à la pression possédant des caractéristiques de transparence optique et auto-réparatrices
US20140220617A1 (en) 2011-04-01 2014-08-07 Children's Medical Center Corporation Dialysis like therapeutic (dlt) device
AU2012284097B2 (en) 2011-07-18 2017-08-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof

Also Published As

Publication number Publication date
US10538562B2 (en) 2020-01-21
EP2526119A2 (fr) 2012-11-28
SG10201503351RA (en) 2015-06-29
SG182577A1 (en) 2012-08-30
US20160200785A1 (en) 2016-07-14
JP2022097536A (ja) 2022-06-30
CA2787376A1 (fr) 2011-07-28
US11059873B2 (en) 2021-07-13
US20180094035A1 (en) 2018-04-05
DK2526119T3 (en) 2018-07-30
US20220056089A1 (en) 2022-02-24
JP6960957B2 (ja) 2021-11-05
US20200299345A1 (en) 2020-09-24
JP2017014194A (ja) 2017-01-19
ES2678143T3 (es) 2018-08-09
JP5959440B2 (ja) 2016-08-02
JP7062723B2 (ja) 2022-05-06
US9150631B2 (en) 2015-10-06
JP2020193201A (ja) 2020-12-03
US20200291083A1 (en) 2020-09-17
US11203623B2 (en) 2021-12-21
WO2011090954A3 (fr) 2012-01-12
EP2526119A4 (fr) 2013-10-02
CN102947341B (zh) 2018-07-06
JP2019142901A (ja) 2019-08-29
WO2011090954A2 (fr) 2011-07-28
JP6513604B2 (ja) 2019-05-15
US20130035283A1 (en) 2013-02-07
US11059874B2 (en) 2021-07-13
US20200095300A1 (en) 2020-03-26
JP2013517327A (ja) 2013-05-16
CN102947341A (zh) 2013-02-27
EP2526119B1 (fr) 2018-05-30
AU2011207626A1 (en) 2012-08-09
AU2011207626B2 (en) 2015-06-18
AU2011207626A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
IN2012DN06589A (fr)
CY1124488T1 (el) Απελευθερωση πρωτεϊνης που βασιζεται σε εξασθενημενης λοιμογονικοτητας βακτηριδια
MY183517A (en) Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
PH12014501776A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
MX366858B (es) Composicion farmaceutica que comprende un complejo de carga con portador polimerico y al menos y un antigeno proteinico o peptidico.
BR112014023005A2 (pt) diagnóstico rápido e tratamentos personalizados para acne
AU2012249274A8 (en) Neutralizing antibodies to Nipah and Hendra virus
EA201001212A1 (ru) Лечение микробных инфекций
CO6630164A2 (es) Proteinas que se unen al tnf-a
IL187321A (en) Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation
BRPI0708101A8 (pt) anticorpos contra a il-22 humana e usos para eles
WO2018116267A3 (fr) Méthodes de traitement avec des anticorps anti-facteur xi/xia
EA201491481A1 (ru) Аллергены тимофеевки луговой и способы и применения для модулирования иммунного ответа
BR112017004059A2 (pt) dispositivo de hemoperfusão utilizável
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
MX2011004483A (es) Leucolectinas y sus usos.
BR112014023642A2 (pt) proteína interferon-lambda4 (ifnl4), moléculas de anticorpo relacionadas, e usos das mesmas
BR112019007147A2 (pt) anticorpos anti-o1 e usos dos mesmos
CY1116962T1 (el) Ανθρωπινες λευκολεκτινες και χρησεις αυτων
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
BR112019002039A2 (pt) anticorpos anti-o2 e uso dos mesmos
Al-Otair et al. Venous thromboembolism in a medical intensive care unit. The effect of implementing clinical practice guidelines
BR112018003252A2 (pt) polipeptídeos mrka, anticorpos, e usos dos mesmos
Ayubi et al. Procalcitonin levels predict identification of bacterial strains in blood cultures of septic patients: effect measures of association
BR112022003623A2 (pt) Proteínas de ligação a cr2 e seu uso em terapia médica